Moreover, in a small DLBCL patients’ dataset (TCGA; n = 47), higher expression of MSI2 exhibited significantly shorter overall survival times compared to those patients with low expression of MSI2 (Supplementary Fig. 3A). This evidence concerns the gene MSI2 and diffuse large B-cell lymphoma.